Natera

What Natera does

Natera, Inc. is a publicly traded (NASDAQ: NTRA) cell-free DNA (cfDNA) testing company founded in 2004 and headquartered in Austin, Texas, with operations in San Carlos, California and (via the Foresight Diagnostics acquisition) Boulder, Colorado. The company operates proprietary molecular and bioinformatics platforms built on multiplexed PCR and next-generation sequencing to detect and quantify circulating tumor DNA, donor-derived cfDNA, fetal cfDNA, and germline variants from a single blood draw. Flagship products include Signatera (tumor-informed, bespoke ctDNA minimal residual disease / MRD assay), Prospera (donor-derived cfDNA with the proprietary Donor Quantity Score algorithm for transplant rejection), Panorama (SNP-based non-invasive prenatal testing), Empower (hereditary cancer screening), Vistara (single-gene NIPT), and Zenith (whole-genome sequencing for rare disease). Natera runs ISO 13485, CAP, and CLIA-certified labs, holds SOC 2 Type II compliance, and is FDA-cleared for the Signatera CDx in muscle-invasive bladder cancer as of May 2026.

Natera generates revenue through clinical testing services billed to payors and health systems (with oncology ASP around $1,250 per Signatera test in Q1 2026), a dedicated BioPharma services unit that licenses Signatera MRD endpoints and provides real-world data access to trial sponsors, and licensing royalties following the April 2026 court award of a 30% royalty on infringing MRD products. Customers span five distinct segments: oncologists and cancer centers (over half of U.S. oncologists use Signatera), women's health providers (OB/GYNs and maternal-fetal medicine specialists), transplant centers, biopharma sponsors (including Allogene, Genentech, Diakonos, CytoDyn, and Purespring), and rare-disease patients via the Zenith platform. The go-to-market motion is direct enterprise field sales to clinicians and health systems, supplemented by channel partnerships (SRL Inc. in Japan, Pirche AG in transplant) and heavy clinical evidence generation that drives guideline inclusion.

The company has processed over 16 million cumulative tests, maintains a proprietary oncology database with 2M+ plasma timepoints, and reports approximately 50% market share in tumor-informed MRD testing. Investment in scientific marketing — 35 abstracts at ASCO 2026, 20 at AACR 2026, 21 at ATC 2026, and 400+ peer-reviewed publications — supports three NCCN guideline recommendations, including Category 1 for Signatera. Q1 2026 revenue of $696.6M (+38.8% YoY) implies TTM revenue of approximately $2.5B and FY2026 revenue in the $2.8B range, with gross margins near 65% and a market capitalization of approximately $30–31B. The announced Austin headquarters expansion (May 2026) will add roughly 400 new roles alongside the company's largest sequencing facility.

Name

Natera

Legal name

Natera, Inc.

Website

https://natera.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Natera is a publicly traded cell-free DNA testing company that provides MRD oncology (Signatera), transplant rejection (Prospera), and reproductive health (Panorama) tests to clinicians, health systems, and biopharma partners, processing over 16 million cumulative tests across its CAP/CLIA-certified laboratories.

Ownership category

akta.pro rank

Headquarters

HQ city

San Carlos

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical diagnostic testing services: Revenue from running cell-free DNA tests (Signatera, Latitude, Altera, Empower, Prospera, Renasight, Panorama, Horizon, Vistara, Anora, Fetal Focus, Zenith) in CAP/CLIA-certified labs for clinicians, hospitals, health systems, and patients. ASPs in oncology testing were approximately $1,250 in Q1 2026, with 54-55% YoY oncology test volume growth.
2. Biopharma services and partnerships: Revenue from biopharma customers using Signatera, CLARITY, and RenasightIQ for clinical trial MRD testing, molecular response analysis, real-world data access, and companion-diagnostic development (e.g., Diakonos, CytoDyn, Allogene, Genentech, Diakonos, Purespring/Travere collaborations).
3. MRD patent licensing royalties: Licensing royalties on MRD-related patents; a U.S. court awarded Natera a 30% ongoing royalty on revenues from infringing MRD-related products (including ArcherDx and Invitae product sales), establishing a recurring royalty revenue stream.
4. Renasight / RenasightIQ pharma research and clinical-trial services: Revenue from genetic testing panels (Renasight kidney gene panel) and pharma research services that accelerate rare-disease and chronic kidney disease clinical trial recruitment (e.g., Alport, ADPKD, FSGS case studies).

Go-to-market motion4 records

Distribution channels5 records

Marketing channels7 records

Core offering

Natera runs cell-free DNA (cfDNA) diagnostic tests in its ISO 13485/CAP/CLIA-certified laboratories, sold to clinicians, health systems, and biopharma customers. Its core franchise is Signatera, a personalized tumor-informed molecular residual disease (MRD) assay for cancer recurrence monitoring, complemented by Prospera dd-cfDNA transplant rejection tests (kidney, heart, lung), Panorama NIPT and women's health reproductive tests, Renasight kidney gene panels, and the Zenith whole-genome rare-disease platform.

Product overview

Natera operates a platform-plus-modules architecture centered on its NateraCore laboratory services infrastructure and NateraConnect provider portal, with the test menu organized into four clinical franchises: (1) Oncology — anchored by Signatera (tumor-informed MRD) and Signatera Genome, complemented by Latitude (tissue-free MRD), Altera (tumor genomic profiling), Spectrum, Empower (hereditary cancer), and the acquired CLARITY MRD assay from Foresight Diagnostics; (2) Transplant — Prospera dd-cfDNA assessment for kidney, heart, and lung recipients; (3) Kidney genetics — Renasight and RenasightIQ panels; and (4) Reproductive health — Panorama NIPT, Vistara, Fetal Focus, Vasistera, Anora, and Horizon carrier screening. Beyond the clinical test menu, the Zenith whole-genome rare-disease platform, Annotation Platform, NEVA educational virtual assistant, ProReach services, and Constellation platform round out the broader offering.

Differentiator

Problem solved

Functional benefit

Brands

• Signatera: Personalized, tumor-informed molecular residual disease (MRD) assay for cancer recurrence monitoring and treatment guidance.
• Latitude
• Altera
• Empower
• Prospera
• Renasight
• Horizon
• Panorama
• Vistara
• Anora
• Vasistera
• Fetal Focus
• Zenith
• Constellation
• NateraConnect
• NateraCore Services
• NEVA for Empower
• Spectrum

Products and services

• Signatera
• Signatera Genome
• Latitude
• Altera
• Empower
• Prospera
• Renasight
• RenasightIQ
• Horizon
• Panorama
• Vistara
• Fetal Focus
• Vasistera
• Anora
• Zenith
• CLARITY MRD Assay
• Spectrum

Quantifiable outcome

• Signatera-positivity associated with HR 8.15 in adjuvant setting and HR 18.30 in surveillance across a meta-analysis of 18 studies, 3,000+ patients, 15 tumor types (ASCO 2026)
• +8 more outcomes

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability9 records

Feature8 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• SRL Inc.coreChannel Partner/ Reseller/ Distributor · 24 June 2026SRL Inc. is Natera's exclusive business partner to commercialize Signatera in Japan following PMDA approval in colorectal cancer. Commercial launch planned by year-end 2026 with SRL supporting commercialization and access expansion across the country.
• Pirche AGcoreStrategic or Co-development Partner · 19 June 2026Pirche AG and Natera announced a strategic collaboration to advance transplant medicine by combining Pirche's TxPredictor pre-transplant immunological risk-stratification platform with Natera's Prospera dd-cfDNA post-transplant monitoring test. Joint launch planned at the 2026 American Transplant Congress.
• CytoDyn Inc.coreStrategic or Co-development Partner · 4 June 2026Natera and CytoDyn announced a strategic collaboration to evaluate circulating tumor DNA (ctDNA) dynamics using Signatera on samples from CytoDyn's CLOVER Phase 2 study in metastatic colorectal cancer, plus access to Natera's proprietary oncology database (2M+ plasma timepoints) for molecular response analysis in leronlimab development.
• Diakonos Oncology Corp.coreStrategic or Co-development Partner · 29 May 2026Natera and Diakonos Oncology Corp. announced a collaboration for Signatera to assess molecular response in patients with refractory melanoma enrolled in Diakonos' DOC-RM Phase I/II trial evaluating DOC1021 (dubodencel), a personalized dendritic cell therapy with FDA Fast Track designation. Natera will perform serial ctDNA monitoring at multiple timepoints.
• NVIDIAcoreTechnology or Integration · 29 May 2026Natera partners with NVIDIA to enhance its AI models for cell-free DNA-based early cancer detection; Natera is cited as a leading example of a biotech that applies AI to cfDNA technology.
• Genentech (Tecentriq)coreStrategic or Co-development Partner · 15 May 2026FDA approval of Genentech's Tecentriq / Tecentriq Hybreza as adjuvant treatment for muscle-invasive bladder cancer patients identified as ctDNA-MRD positive by Natera's Signatera CDx, supported by the IMvigor011 Phase III study (36% reduction in recurrence or death; 41% reduction in overall death).
• Purespring Therapeutics (with Bristol Renal / Genescape / Travere Therapeutics)minorStrategic or Co-development Partner · 29 April 2026Natera collaborated on Purespring Therapeutics' publication in Kidney International Reports identifying NPHS2 variants as a significant under-recognised cause of adult-onset FSGS, informing development strategy for Purespring's PS-001 candidate treatment.
• BGI Genomics Co., Ltd.coreStrategic or Co-development Partner · 27 April 2026Strategic collaboration with BGI Genomics for developing NGS-based genetic testing assays, cited as a key partnership in stock analyses of Natera.
• Allogene TherapeuticscoreStrategic or Co-development Partner · 13 April 2026Natera's CLARITY MRD assay is being used to identify MRD-positive patients in Allogene Therapeutics' registrational ALPHA3 trial of cema-cel in first-line large B-cell lymphoma. Interim futility analysis showed 58.3% MRD clearance in the cema-cel arm vs. 16.7% observation.
• MyOmecoreStrategic or Co-development Partner · 12 March 2026Exclusive partnership with MyOme to develop Natera's Zenith whole-genome sequencing rare-disease platform, designed to shorten the 4-7 year diagnostic odyssey for rare disease patients.

Scale indicators16 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Guardant Health: Direct competitor in blood-based cancer diagnostics. Guardant360 (liquid biopsy CGP) and Guardant Reveal (tumor-naive MRD assay) overlap with Natera's Altera and Signatera franchises, targeting the same oncologists and biopharma partners.
• Exact Sciences: Oncology diagnostics competitor with Cologuard (CRC screening), the Thrive/Earli detection platform, and Oncodetect MRD. Competes for the same clinician wallet and biopharma companion-diagnostic relationships as Natera's oncology franchise.
• Adaptive Biotechnologies: Competitor in MRD with the FDA-approved clonoSEQ assay for hematologic malignancies (ALL, MM, CLL). Also offers T-cell receptor immunodiagnostics. Direct overlap with Natera's hematology MRD work via CLARITY (acquired with Foresight).
• Caris Life Sciences: Competitor in molecular profiling (MI Profile, MI Cancer Seek) and AI-driven multi-omics. Targets oncology clinicians and biopharma with similar use cases to Natera's Altera and CLARITY franchises.
• Myriad Genetics: Genetic testing competitor with overlapping prenatal/women's health (Foresight, Prequel), hereditary cancer, and oncology products. Direct overlap with Natera's Panorama, Horizon, Empower, and Vistara franchises.
• CareDx: Direct competitor in transplant diagnostics with AlloSure (dd-cfDNA) for kidney and heart transplant monitoring. Competes head-to-head with Natera's Prospera in the same transplant centers and is also an active IP adversary.

Broad incumbents

• Foundation Medicine: Roche subsidiary and broad incumbent in comprehensive genomic profiling (FoundationOne CDx, FoundationOne Liquid CDx). Competes with Natera's Altera and Signatera within oncology workflows and has deep pharma/biopharma penetration.
• NeoGenomics: Oncology-focused clinical laboratory services company offering CGP, MRD (RaDaR), and hematology testing. Competes with Natera in oncology hospital and biopharma channels; broader menu but less MRD-specific depth.

Emerging players

• Tempus AI: AI-enabled precision medicine company offering genomic profiling, real-world data, and biopharma services. Adjacent competitor to Natera's biopharma services business, with overlapping pharma clients but a different technical foundation (DNA/RNA + imaging vs. cfDNA).
• Veracyte: Genomic diagnostics company focused on urology (Decipher Prostate), thyroid, and lung. Increasingly competing with Natera's oncology CGP and emerging MRD urology applications, with similar sales motion into specialist clinicians.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/NateraGenetics
• Facebookfacebook.com/NateraGenetics
• LinkedInlinkedin.com/company/1051903
• Instagraminstagram.com/nateragenetics

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Subsidiaries1 record

Funding overview

Funding rounds14 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Natera